BridgeBio shares rise 25% after FDA approval of Attruby. $BBIO (+0,47%)
The company is currently seeking marketing authorization for Attruby. DAX-listed Bayer is also likely to be keeping a close eye on the approval process. The Leverkusen-based company secured the exclusive marketing rights to Acoramidis for the European market in March for 310 million dollars in the form of an upfront payment and short-term milestone payments. $BAYN (+0,17%)
BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares rose 25% after the company received approval from the U.S. Food and Drug Administration (FDA) for Attruby™ (Acoramidis). Attruby is an oral medication for the treatment of adults with ATTR-CM that aims to reduce cardiovascular deaths and hospitalizations. The approval is based on the positive results of the ATTRibute-CM Phase 3 trial.
